drugset / Trial / NCT01244217
Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Primary Objective: \- To evaluate safety (4 weeks) Secondary Objectives: * To evaluate the long-term safety (12 weeks) * To evaluate the efficacy * To characterize the pharmacokinetic profile
Timeline
- Start
- 2010-10
- Primary completion
- 2011-07
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fexofenadine | Unknown | 15 mg | Oral |
| Subject | Fexofenadine | Unknown | 30 mg | Oral |